| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Crovalimab (anti-Complement C5)
CAS:1917321-26-6
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14117
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Crovalimab
CAS:1917321-26-6
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Crovalimab
CAS:1917321-26-6
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Crovalimab (DHB90005)
CAS:1917321-26-6
Purity:PAGE:>95% Package:100ug;1mg
|
|
| | Crovalimab Basic information |
| Product Name: | Crovalimab | | Synonyms: | Crovalimab;Research Grade Crovalimab (DHB90005);Research Grade Crovalimab;Crovalimab (anti-Complement C5) | | CAS: | 1917321-26-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Crovalimab Structure]() |
| | Crovalimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Crovalimab Usage And Synthesis |
| Uses | Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2?nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research[1][2]. | | in vivo | Crovalimab (SKY59; RO7112689; 20?mg/kg; iv; only once at day 0) completely prevents accumulation of plasma C5 in cynomolgus monkeys. SKY59-IgG1 (SG115) shows slower clearance: 1.87?mL/day/kg[1].
Crovalimab (20?mg/kg; iv; a single dose) stably suppressed complement activity in plasma for 8 weeks[1].
Crovalimab (5?mg/kg by iv at day 0 and 2?mg/kg by sc at day 7, 21, 35, 49, and 63) causes over 20% of serum hemolytic activity in the cRBC lysis assay to correlate with events such as dysphagia and dramatic increases in lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) levels[1].
| | References | [1] Taku Fukuzawa, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017 Apr 24;7(1):1080. DOI:10.1038/s41598-017-01087-7
[2] Wioleta M Zelek, et al. Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology. 2018 Nov;155(3):396-403. DOI:10.1111/imm.12982 |
| | Crovalimab Preparation Products And Raw materials |
|